Journal of Bone Biology and Osteoporosis最新文献_第2页

Young Population Attending for Whole Body Technetium 99MDP Bone Scintigraphy: A Single Institution Experience 年轻人参加全身锝99MDP骨显像:单一机构的经验

Journal of Bone Biology and Osteoporosis Pub Date : 2018-09-06 DOI: 10.18314/JBO.V4I1.1296

Hosam Halim, A. Halim, R. Hamed

{"title":"Young Population Attending for Whole Body Technetium 99MDP Bone Scintigraphy: A Single Institution Experience","authors":"Hosam Halim, A. Halim, R. Hamed","doi":"10.18314/JBO.V4I1.1296","DOIUrl":"https://doi.org/10.18314/JBO.V4I1.1296","url":null,"abstract":"Objective: Radionuclide isotope scanning is a sensitive scanning procedure for the detecting of bone pathology. This article focuses on an institution experience bone Scintigraphy applications in patients below 25 years.Patients and methods: This study is a retrospective descriptive study that analyzed the handwritten medical records of patients younger than 25 years old referred for Technetium bone scan in Mansoura University Hospital, Nuclear Medicine Unit from August 2011 to October 2015.Results: Seventy-six patients younger than 25 years old were referred for bone scan. The main cause of referral was metastatic work up. Osteosarcomas and Ewing tumors constituted together the commonest malignant tumors referred while osteochondromas were the commonest benign tumors. The area around the knee was the commonest affected area in the primary bone neoplasm’s while the vertebrae and the pelvis were the commonest sites of distant metastasis. No recorded complications existed secondary to the injection of the radioactive material. The commonest defect was lack of documentation of the family history.Conclusion: This study helped to elucidate the extent of medical support that our nuclear medicine unit can give to other pediatric and adolescent medical specialties. It demonstrates also the wise selection of the cases to be referred for bone scan. To maximize the benefit from our bone scan service, analysis of differences between our unit and older larger units in the country is needed as regard policy decisions and financing. Digital reporting will put an end to mistakes in handwritten patient records.","PeriodicalId":249116,"journal":{"name":"Journal of Bone Biology and Osteoporosis","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131866194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of Chromeceptin on Insulin-like Growth Factor II in Human Osteoblastic and Osteosarcoma Cells 铬蛋白酶对人成骨细胞和骨肉瘤细胞中胰岛素样生长因子II的影响

Journal of Bone Biology and Osteoporosis Pub Date : 2018-08-10 DOI: 10.18314/JBO.V4I1.1219

R. Dziak, Dalia Nourah, That AlHousami, D. Nguyen

{"title":"Effects of Chromeceptin on Insulin-like Growth Factor II in Human Osteoblastic and Osteosarcoma Cells","authors":"R. Dziak, Dalia Nourah, That AlHousami, D. Nguyen","doi":"10.18314/JBO.V4I1.1219","DOIUrl":"https://doi.org/10.18314/JBO.V4I1.1219","url":null,"abstract":"The insulin-like growth factor system is a complex regulatory system of insulin-like growth factors I and II (IGF-I and IGF-II) as well as their cell surface receptors and a family of insulin growth factor binding proteins (IGF-BPs). Despite extensive research on the IGF system in skeletal tissue, there is still not a complete understanding particularly of the role of IGF-II in the regulation of normal and pathological osseous cells in human skeletal biology. The purpose of this study was to further delineate the possible involvement of IGF-II in the regulation of human normal calvarial osteoblasts and G292 human osteosarcoma cellular activity using exogenously added IGF-II as well as a drug, Chromeceptin that has been shown in some other cellular systems to down regulate endogenous IGF-II levels.The results presented here show a similar dose dependent effect of Chromeceptin on inhibition of endogenous IGF-II levels (measured with an immunoassay) and cellular activity (measured with the MTT assay) in both the normal and osteosarcoma cells while small significant increases in activity with exogenously added IGF-II were observed only in the osteosarcoma cells. Moreover, IGF-BP1 levels (measured with an immunoassay) were shown to significantly increase in the G292 cells in a similar manner previously reported in other cell systems with only minor non-significant effects of exogenously added IGF-BP1 in the osteosarcoma cells studied here. These studies suggest that endogenous IGF-II is a critical regulator of activity in both normal and osteosarcoma cells and Chromeceptin can be an effective pharmacological agent for further studies on the role of the growth factor in human skeletal systems.","PeriodicalId":249116,"journal":{"name":"Journal of Bone Biology and Osteoporosis","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126611788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Continuing Relief of Pain with Long Term Treatment for Osteoporosis with Intravenous Pamidronate 长期静脉注射帕米膦酸钠治疗骨质疏松患者疼痛的持续缓解

Journal of Bone Biology and Osteoporosis Pub Date : 2018-08-10 DOI: 10.18314/JBO.V4I1.1264

S. Wilson, Sharp Ca, Davie Mwj

{"title":"Continuing Relief of Pain with Long Term Treatment for Osteoporosis with Intravenous Pamidronate","authors":"S. Wilson, Sharp Ca, Davie Mwj","doi":"10.18314/JBO.V4I1.1264","DOIUrl":"https://doi.org/10.18314/JBO.V4I1.1264","url":null,"abstract":"Purpose: Bisphosphonates are valuable in reducing the incidence of fracture. Side effects limit persistence with oral therapy and long term studies of pain relief are difficult to pursue. Intravenous bisphosphonates offer an alternative treatment to oral bisphosphonates and are tolerated over a longer period. The use of Pamidronate, an intravenously administered bisphosphonate, to benefit pain and reduce fracture incidence in the long term has not been extensively investigated. The study aimed to investigate the effect of Pamidronate on pain, vertebral fracture incidence and Bone Mineral Density over 6 or more years.Methods: Patients were offered intravenous Pamidronate if oral treatment with bisphosphonates or Hormone replacement therapy had failed due to side effects, fractures continued on oral treatment or oesophageal reflux led to cessation of oral treatment. Pain was assessed using the Nottingham health profile; radiographs were used to evaluate vertebral fracture and DXA measured bone mineral density.Results: The primary outcome was the pain domain. Median patient follow up was 9 years. Pain had improved significantly (p = 0.03) and in 68% pain had either improved or remained unchanged. Vertebral fractures occurred in 14% of patients in the first 3 years, 9.5% in years 4-6, but increased in years 7-9 to 27%. Bone mineral density increased in the lumbar spine (p < 0.001) but not at the femoral neck.Conclusions: Pamidronate had a beneficial effect on pain over the period of the study. Vertebral fracture incidence increased after 6 years of Pamidronate, although spine BMD increased significantly.","PeriodicalId":249116,"journal":{"name":"Journal of Bone Biology and Osteoporosis","volume":"36 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127069289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cutting Edge of Herbal Drugs over Allopathic Drugs in Clinical Treatment of Rheumatoid Arthritis 类风湿关节炎临床治疗中草药相对于对抗药物的优势

Journal of Bone Biology and Osteoporosis Pub Date : 2018-08-06 DOI: 10.18314/jbo.v4i1.1194

V. Ashwlayan, Saurabh Nimesh

引用次数: 1

Problems with the Use of Aromatase Inhibitors in Breast Cancer 芳香化酶抑制剂在乳腺癌中应用的问题

Journal of Bone Biology and Osteoporosis Pub Date : 2018-07-26 DOI: 10.18314/JBO.V4I1.1184

J. Stark

{"title":"Problems with the Use of Aromatase Inhibitors in Breast Cancer","authors":"J. Stark","doi":"10.18314/JBO.V4I1.1184","DOIUrl":"https://doi.org/10.18314/JBO.V4I1.1184","url":null,"abstract":"The use of Aromatase Inhibitors (AI’s) in the adjuvant therapy of operable breast cancer is ubiquitous. All guidelines in widespread use advocate their use in hormone-receptor-positive breast cancer in post-menopausal women. Premenopausal hormone-receptor-positive women who are considered at high risk of relapse are also treated with drug- or surgically-induced ovarian suppression plus an AI following chemotherapy, producing somewhat better results than those seen with chemo followed by tamoxifen [1]. A major side effect of these drugs is the accelerated loss of bone mineral density (BMD). The use of bone-sparing agents such as bisphosphonates has become widespread but not routine in these patients. Whether or not they receive bone-sparing agents, patients on AI’s should receive periodic assessment of bone density. How do doctors comply with this common-sense approach? The answer: not as often as they should. The best data on this practice was published in the Journal of Oncology Practice in May 2017 from a group of investigators at Yale [2]. Using the SEER Medicare database they identified over 135,000 women diagnosed with breast cancer from 2007 to 2010. Using robust exclusion criteria for such things as metastasis at presentation, too brief exposure to bisphosphonates, in situ only cancer, and prior diagnosis of osteoporosis, they identified 2409 women who met all entry criteria and served as the population studied. Within this group only 51% received a DEXA scan at initiation of AI and only 34% had a second scan within three years of being on therapy. What the authors were not able to ascertain was how many of these patients were placed on a prophylactic bisphosphonate or equivalent at the start of AI therapy. What was clear is that age and race had a lot to do with who received a DEXA scan. 30% of women over 85 vs. 56% ages 67-69 were scanned. 53% of causasian women were scanned vs. 33% non-caucasian. Wonen with higher stage and more comorbidities were also less likely to have been scanned.","PeriodicalId":249116,"journal":{"name":"Journal of Bone Biology and Osteoporosis","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134381653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient with Metastatic Process in the Skeleton of Unknown Etiology 病因不明的骨骼转移过程患者

Journal of Bone Biology and Osteoporosis Pub Date : 2016-07-01 DOI: 10.18314/JBO.V5I1.1794

M. Majernikova, J. Sedláček, Z. Monhart

引用次数: 0